Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13431734 | 1.00 | SRC (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL248434 | 1.00 | SRC (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL12134271 | 0.82 | SRC (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL11462913 | 0.82 | SRC (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL8400939 | 0.81 | SRC (0.54) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL974061 | 0.79 | SRC (0.52) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL11404609 | 0.79 | SRC (0.52) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL14686240 | 0.77 | CYP2D6 (0.50) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL103235 | 0.77 | ALDH1A1 (0.54) | SRCCYP2D6LMNAMAPK1PPARA | |
| SCHEMBL155984 | 0.77 | ALDH1A1 (0.54) | SRCCYP2D6LMNAMAPK1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021895-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-07-06 | — | — | EP | claimed |
| WO-2021037868-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-04 | — | — | WO | claimed |
| EP-4021895-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3875594-A1 | PREPARATION METHOD FOR (R)-O-CHLOROMANDELIC ACID AND CYCLIC BIOENZYME CATALYTIC REACTION SYSTEM FOR THE PREPARATION METHOD | Wuhan Wuyao Pharmaceutical Co., Ltd. (CN) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021037868-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-04 | — | — | WO | disclosed |
| EP-2532665-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XUANZHU PHARMA CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2016-06-23 | — | — | US | disclosed |
| US-9315513-B2 | Benzimidazole derivatives and their pharmaceutical compositions and uses | Xuanzhu Pharma Co., Ltd. (CN) | 2016-04-19 | — | — | US | disclosed |
| EP-2413711-B1 | DIPEPTIDE AS FEEDSTUFF ADDITIVE | EVONIK DEGUSSA GMBH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20140205711-A1 | DIPEPTIDES AS FEED ADDITIVES | EVONIK DEGUSSA GMBH (DE) | 2014-07-24 | — | — | US | disclosed |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | Xuanzhu Pharma Co., Ltd. (CN) | 2013-01-24 | — | — | US | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| CN-1085556-A | The 4-pyrimidyl and the pyridinyl derivatives of the indol-3-yl alkylpiperazine of anti-migraine | BRISTOL MYERS SQUIBB CO (US) | 1994-04-20 | — | — | CN | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| US-4904065-A | Liquid crystal optical element and method of producing the same using ferroelectric polymer liquid crystal | IDEMITSU KOSAN CO., LTD. (JP) | 1990-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | F12, HRH2, H1-3 | SRC 4276/4885CYP2D6 152/4885LMNA 1847/4885 |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | F12, HRH2, H1-3 | SRC 4276/4885CYP2D6 152/4885LMNA 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.